Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously rece...
Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses t...
Expected to be immediately accretive to Adjusted Earnings Per Share (EPS)¹ after close Attractive return profile given high growth and strong margi...
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune dise...
Avance Clinical, the award-winning Australian led, global CRO built exclusively to service the clinical research needs of biotech companies, announced th...
Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter Neurosciences, Inc , a clinical...
- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with ...
-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose ...
Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solution...
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high t...
Sterile fill/finish capacity added in Lee, MA, and injectable assembly and packaging capacity added in the Netherlands, Belgium, Allent...
SALVAT receives FDA approval for Clotic®, an innovative treatment for otomycosis with Orphan Drug Designation Th...
Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...
© 2025 Biopharma Boardroom. All Rights Reserved.
